News Exact Sciences Corporation

Equities

EXAS

US30063P1057

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-05-22 pm EDT			5-day change	1st Jan Change
56.48 ^USD	-0.72%		+0.55%	+0.52%

May. 22	Exact Sciences Corp. Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025	CI
May. 14	Exact Sciences Corporation Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 10:40 AM

Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025	May. 22	BU
Exact Sciences Corp. Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025	May. 22	CI
Exact Sciences : Latest Corporate Presentation	May. 16	PU
Exact Sciences Corporation Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 10:40 AM	May. 14
Exact Sciences Earns 2025 Great Place To Work® Certification™	May. 12	BU
US FDA approves first at-home test for cervical cancer screening	May. 09	RE
RBC Raises Price Target on Exact Sciences to $54 From $52, Keeps Sector Perform Rating	May. 02	MT
Exact Sciences to Participate in May Investor Conference	May. 02	BU
Exact Sciences Q1 Adjusted Loss Narrows, Revenue Rises; Shares Up	May. 01	MT
Exact Sciences Corporation, Q1 2025 Earnings Call, May 01, 2025	May. 01
Exact Sciences: Q1 Earnings Snapshot	May. 01	AQ
Exact Sciences Announces First-Quarter 2025 Results	May. 01	BU
Earnings Flash (EXAS) Exact Sciences Posts Q1 Loss $-0.21 Per Share, vs. FactSet Est of $-0.25	May. 01	MT
Earnings Flash (EXAS) Exact Sciences Posts Q1 Revenue $706.8M, vs. FactSet Est of $688.6M	May. 01	MT
Exact Sciences Corporation Revises Earnings Guidance for the Year 2025	May. 01	CI
Exact Sciences Corporation Reports Unaudited Consolidated Impairment of Long-Lived and Indefinite-Lived Assets for the First Quarter Ended Mar. 31, 2025	May. 01	CI
Exact Sciences Corporation Reports Earnings Results for the First Quarter Ended March 31, 2025	May. 01	CI
Exact Sciences Corporation Appoints Leslie Trigg as A Class II Member of the Board	Apr. 29	CI
Exact Sciences to Highlight Cologuard® Test Adherence and Predicted Preference Data at Digestive Disease Week (DDW) 2025	Apr. 29	BU
Exact Sciences Launches the Oncodetect™ Molecular Residual Disease Test	Apr. 22	BU
Exact Sciences Launches the Oncodetect Molecular Residual Disease Test	Apr. 22	CI
Exact Sciences Corp. - JAMA Oncology Publication Strengthens Evidence for Oncotype DX Test Reliability across Racial and Ethnic Groups	Apr. 15	AQ
JAMA Oncology Publication Strengthens Evidence for Oncotype DX® Test Reliability Across Racial and Ethnic Groups	Apr. 14	BU
Exact Sciences Corp. Announces Publication of Comprehensive Review in JAMA Oncology That Strengthens the Evidence Supporting the Oncotype DX Breast Recurrence Score Test	Apr. 14	CI
Mizuho Initiates Exact Sciences at Outperform With $60 Price Target	Apr. 10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Exact Sciences Corporation

Equities

EXAS

US30063P1057

Biotechnology & Medical Research

Filters